Evolving Paradigms of Therapy for Multiple Myeloma: State of the Art and Future Directions - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34110937/

This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable....

Inhibition of Pim-2 kinase by LT-171-861 promotes DNA damage and exhibits enhanced lethal effects with PARP Inhibitor in multiple myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34111425/

Multiple myeloma (MM) is a malignancy of antibody-producing plasma cells with genomic instability and genetic abnormality as its two hallmarks. Therefore, DNA damage is pervasive in MM cells, which indicates...

Population Pharmacokinetics of Belantamab Mafodotin, a BCMA-targeting Agent in Patients with Relapsed/Refractory Multiple Myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34076364/

Belantamab mafodotin (belamaf) is an antibody-drug conjugate (ADC) targeting B-cell maturation antigen (BCMA). Nonlinear mixed-effects models were developed to characterize the population pharmacokinetics (PopPK) of ADC, total monoclonal antibody (mAb),...

Review of Venetoclax in CLL, AML and Multiple Myeloma - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34073976/

Venetoclax is a highly selective and effective B-cell lymphoma-2 (BCL-2) inhibitor, which is able to reinstate the apoptotic potential of cancer cells. With its full repertoire yet to be explored,...

KDM2A Targets PFKFB3 for Ubiquitylation to Inhibit the Proliferation and Angiogenesis of Multiple Myeloma Cells - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/34079757/

The lysine demethylase KDM2A (also known as JHDM1A or FBXL11) demethylates histone H3 at lysine K36 which lead to epigenetic regulation of cell proliferation and tumorigenesis. However, many biological processes...